Multimodality Treatment Based on Induction Chemotherapy for Stage III NSCLC.
- Author:
Yeun Seun LEE
1
;
Pil Soon JANG
;
Hyun Mo KANG
;
Jeung Eyeun LEE
;
Ju Moon JO
;
Pyeung Seung LIM
;
Sung Soo JUNG
;
Ju Ock KIM
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, College of Medicine & Cancer Research Institute, Chungnam National University, Daejeon, Korea. sykin@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Induction chemotherapy;
Locally advanced non-small cell lung cancer
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Disease Progression;
Drug Therapy;
Follow-Up Studies;
Humans;
Induction Chemotherapy*;
Neutropenia;
Radiotherapy;
Thorax;
Tomography, X-Ray Computed
- From:Journal of Lung Cancer
2005;4(2):81-88
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE : The aim of this study was to validate the effect and the feasibility of induction chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) on multimodality treatment. MATERIALS AND METHODS : From January 2002 to December 2003, 84 chemonaive patients with Stage III NSCLC, median age of 64 years, ECOG perfomance satus 0, 1, or 2, and without other comorbid disease were enrolled this study and received chemotherapy every 3 weeks. After two or three cycles of induction chemotherapy (gemcitabine with cisplatin), patients were reevaluated by chest CT and then underwent resection, radiotherapy, further chemotherapy, or observation. RESULTS : Overall clinical responses were seen in 43 (57%) of the 76 assessable patients. Response rates were 61% and 53% in patients with stage IIIA and IIIB disease, respectively. Twenty-eight patients out of initially unresectable 70 patients (19 of 32 stage IIIA and 9 of 38 stage IIIB) after induction chemotherapy seemed to be resectable. Operation was done in 23 out of 32 patients who achieved clinically resectable stage after induction chemotherapy and 20 (87%) resections were complete and 3 were incomplete including 1 case of open & closure. Thirty-two patients were treated with chest radiation after chemotherapy. Eighteen patients were treated with chemotherapy upto 6 cycles and 6 patients refused further treatment after induction chemotherapy. Median follow up of all patients was 16.2 months, median survival was 16 months, and estimated disease progression free interval was 11 months. Survival and disease progression free interval were different with between induction chemotherapy followed by complete resection subgroup and followed by radiation therapy subgroup (24 vs. 14 months, p=0.04). Grade 3/4 neutropenia and thrombocytopeina were noticed in 29% and 10%, respectively and one chemotherpy related death was also noticed. CONCLUSION : Induction chemotherapy followed by surgery with or without adjuvant radiation might be the recommendable management to improve the survival in locally advanced NSCLC with feasible toxicity
